Caitong International Asset Management’s Estrella Immunopharma ESLA Stock Holding History

Caitong International Asset Management’s Portfolio ESLA Stock Details ESLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2	Buy	+2	New	+$3	﹤0.01%	2824

Other funds holding ESLA

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Caitong International Asset Management's ESLA Position: Q2 2026 in Review

Caitong International Asset Management opened a new position in Estrella Immunopharma (ESLA) in Q2 2026: 2 shares worth $2. The stake represents ﹤0.01% of the portfolio and ranks #2824 among its holdings.

15 funds tracked by Wall St. Rank hold ESLA as of Q2 2026.

Caitong International Asset Management held 2 shares of Estrella Immunopharma worth $2 as of Q2 2026.
Estrella Immunopharma was a new Caitong International Asset Management position in Q2 2026.
Estrella Immunopharma made up ﹤0.01% of Caitong International Asset Management's portfolio in Q2 2026, its #2824 holding.
15 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2026.

Based on Caitong International Asset Management's 13F filing for Q2 2026, filed 5 Aug 2026.